Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PPIB | P23284 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154107 | 0.91 | PPIB (0.40) | MASP2DPP4KCNH2MEN1KMT2A | |
| SCHEMBL1431769 | 0.91 | DPP4 (0.39) | MASP2DPP4KCNH2MEN1KMT2A | |
| SCHEMBL1432630 | 0.91 | DPP4 (0.39) | MASP2DPP4KCNH2MEN1KMT2A | |
| SCHEMBL1433063 | 0.91 | HDAC1 (0.44) | MASP2DPP4KCNH2MEN1KMT2A | |
| SCHEMBL1432209 | 0.90 | F2 (0.42) | MASP2DPP4KCNH2MEN1KMT2A | |
| SCHEMBL1432780 | 0.90 | F2 (0.42) | MASP2DPP4KCNH2MEN1KMT2A | |
| SCHEMBL1432074 | 0.90 | DPP4 (0.38) | MASP2DPP4KCNH2MEN1KMT2A | |
| SCHEMBL1432028 | 0.90 | HDAC1 (0.40) | DPP4KCNH2MEN1KMT2AXIAP | |
| SCHEMBL1432174 | 0.90 | DPP4 (0.38) | MASP2DPP4KCNH2MEN1KMT2A | |
| SCHEMBL1432180 | 0.88 | DPP4 (0.40) | MASP2DPP4KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | MASP2 3039/4885DPP4 1063/4885KCNH2 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.